Thanks to the assiduousness of talented researchers around the globe, our contemporary understanding of the pharmacology and probably also the physiological regulation of growth hormone secretion, came about after the important discovery that GHRP increased pulsatile GH secretion in not only children, but also within normal younger and older men and women. Even though GHRP alone substantially releases GH from the pituitary in vitro without the addition of GHRH, this rhythmic endogenous secretion does require some GHRH.


Adults do not stop producing growth hormone as they get older; in fact, it's a myth that's spread by the HRT/TRT industry. However, as you get older, it's harder to activate the body’s release or pulse of growth hormone as frequently as you did when you were still growing; hence, the term “when I was younger...”. Who doesn't remember how great they felt at 18, versus 38!


© 2010-2017 Copyright HGH.com and Purity Select, Inc. None of our statements have been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease. All products sold on this web site are intended for adults over the age of 18 and are not to be used by children under the age of 18. We do not have any clinical studies backing up our claims. Individual results will vary. Do not use more than the daily dose recommended on the label of each product. Please speak with your primary care physician before purchasing or starting the use of any supplement.
Molly Hunsinger is a communications professional and certified group exercise instructor and fitness trainer. Her medical, health and fitness industry background spans nearly three decades with experience working as an instructor trainer, staff trainer, facility manager, group exercise program manager, physician relations manager and marketing director. As a media professional, she has developed and launched award-winning allied marketing and advertising campaigns for luxury retailers, leading nonprofit organizations and foundations and written numerous articles and blogs for both digital and print publications. Molly holds a bachelor’s degree in mass communications from the University of South Florida with a concentration in journalism and digital media studies.
The response to GHSs is not gender related, except during puberty, when girls exhibit a greater response than do boys. The GH responses to both GHSs and ghrelin are similar during the early-follicular, late-follicular, and luteal phases of the menstrual cycle, suggesting that they are not affected by changes in estrogen levels. However, estrogen as well as estrogen-progestin supplementation enhances the GH response to ghrelin after menopause.

CJC 1295 is a fast working growth hormone releasing hormones devised to reduce the effects of ageing. It works by stimulating the body’s natural growth hormone production and the release of IGF-1. The advantages of the CJC peptide is it helps increases bone density and collagen, as well as boosting the immune system. It will also produce new muscle cells which will be leaner and increases weight loss. The CJC 1295 results are part of years of scientific studies. It primarily increases the production of proteins, which leads to stable bodily functions related to the glands in the body or the endocrine system.
GHRP-6 is most commonly provided in small vials of 5 mg, which should be stored under refrigeration. (It is acceptable however for them to be mailed unrefrigerated.) The vial is diluted with a convenient volume of sterile or bacteriostatic water. For example, the vial might be diluted with 2.5 mL of water, yielding a solution of 2 mg/mL (2000 mcg/mL.) After the water addition, the vial again will be stored under refrigeration.
for teeth whitening products containing between 3 per cent to 6 per cent of hydrogen peroxide and between 9 per cent to 18 per cent of carbamide peroxide to be only legally accessible from a registered health practitioner. Patients to be permitted to use these products 'at home' only after consultation with their registered health practitioner; and
Three of the submissions did not support the proposal highlighting the impact the change in scheduling would have on product currently on the market, industry, pharmacists and consumers. Two submissions noted that there has not been a history of concern with this combination of substances. One submission, referring to the NEJM article, believed that a lack of information about the study means that it cannot be relied upon as there is not a meaningful assessment of the results.
From the examination of many studies, the saturation GHRP-6 doses have been determined to be 1mcg per kg of body weight, and an average dose of approximately 100mcg without concern for bodyweight[1] [2] [3] [4]. That is to say that a 100mcg saturation dose of GHRP-6 will fully saturate receptors, and that 200mcg will only provide 50% additional effectiveness, and a 300mcg dose will provide only 25% additional effectiveness, and so on and so forth. This is very much the case with almost all GHRPs and GHRH analogues, as it seems to be the nature of these peptides.

Superior SARMS products are manufactured to be a safe and effective steroid and peptide alternative. Unlike androgenic drugs such as traditional anabolic steroids, Superior SARMS are  much more selective in their action as they directly target androgen receptors in muscle, bone, body fat and connective tissues in the body.  Our products increase the metabolic rate within the body without disturbing its natural hormones, which in turn greatly assist in achieving maximum results such as lean muscle gain and enhanced muscle recovery along with the added benefits of anti-aging effects, further with regenerating overall connective tissue and repair. All Superior SARMS products are also orally administered with no intravenous injections. It must be noted that Superior SARMS are for “Research Purposes Only”.
Growth hormone (GH) was first identified for its notable effect on longitudinal growth. Subsequent research revealed that the GH has anabolic effects on protein, lipid, and carbohydrate metabolism. GH replacement therapy, using recombinant GH, is therefore used to treat individuals with short stature due to a variety of conditions. However, GH replacement therapy suffers from significant drawbacks such as low bioavailability and side effects. Moreover, most GH-deficient individuals exhibit a secretory defect rather than a primary deficiency in GH production. Research seeking a better drug to replace GH was therefore extensively active in the 1980s and 1990s.
It has been discovered that when GHRP-6 and insulin are administered simultaneously, GH response to GHRP-6 is increased (1). However, the consumption of carbohydrates and/or dietary fats, around the administration window of GH secretagogues significantly blunts the GH release. A recent study in normal mice showed significant differences in body composition, muscle growth, glucose metabolism, memory and cardiac function in the mice being administered the GHRP-6 (2). There are still many questions regarding this fairly new compound, scientists are hoping to gain a better clinical understanding of the peptide through further research over the next few years.
×